ASH 2018 | CAR-T and ibrutinib in combination: a promising treatment for CLL
Lydia Scarfò, MD, of the Vita-Salute San Raffaele University, Milan, Italy, describes the new challenge of chronic lymphocytic leukemia (CLL) patients relapsing with novel agents. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Scarfò discusses how the use of CAR T-cell therapy is promising in terms of disease control and response, with improved efficacy when combined with ibrutinib, and therefore could be a mainstay in future therapy for CLL.
